

Cover Story
ClinicalReal-world Evidence
By Matthew Bin Han Ong
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
In Brief


Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for October 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
- ACOG says it will no longer accept federal funding
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- The Med Student’s Memo – Research Concerns
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts